Patient characteristics
| . | All (N = 55) . | Phase 1b (n = 25) . | Phase 2 (N = 30) . |
|---|---|---|---|
| Median age, y (range) | 60 (19-84) | 58 (19-84) | 67 (23-81) |
| Male/female, n/n | 35/20 | 17/8 | 18/12 |
| ECOG performance status, n (%) | |||
| 0-1 | 48 (87%) | 23 (92%) | 25 (83%) |
| 2 | 7 (13%) | 2 (8%) | 5 (17%) |
| Stage | |||
| I-II | 9 (16%) | 6 (24%) | 3 (10%) |
| III-IV | 46 (84%) | 19 (76%) | 27 (90%) |
| Previous lines of antineoplastic therapy, n (%) | |||
| 1 | 13 (24%) | 5 (20%) | 8 (27%) |
| 2 | 19 (35%) | 9 (36%) | 10 (33%) |
| ≥3 | 23 (42%) | 11 (44%) | 12 (40%) |
| Median, n (range) | 2 (1-11) | 2 (1-11) | 2 (1-6) |
| Prior therapies | |||
| Brentuximab vedotin, n (%) | 13 (24%) | 7 (28%) | 6 (20%) |
| AutoSCT/alloSCT, n (%) | 13 (24%) | 7 (28%) | 6 (20%) |
| Checkpoint inhibitor, n (%) | 9 (16%) | 5 (20%) | 4 (13%) |
| HDACi, n (%) | 5 (9%) | 3 (12%) | 2 (7%) |
| EBV CTL | 5 (9%) | 2 (8%) | 3 (10%) |
| Refractory to most recent regimen, n (%) | 41 (75%) | 17 (68%) | 24 (80%) |
| EBV+lymphoma diagnosis | |||
| B-NHL, n (%) | 10 (18%) | ||
| DLBCL, n | 7 | ||
| Other B-cell, n | 3∗ | ||
| T/NK-NHL, n (%) | 21 (38%) | ||
| Extranodal NK/T-cell lymphoma | 9 | ||
| PTCL NOS | 5 | ||
| Angioimmunoblastic T-cell lymphoma | 6 | ||
| Cutaneous T-cell lymphoma | 1 | ||
| Immunodeficiency-associated LPD, n (%) | 13 (24%) | ||
| Posttransplant lymphoproliferative disorder | 4 | ||
| Systemic lupus erythematosus | 2 | ||
| Common variable immune deficiency | 1 | ||
| Primary immunodeficiency | 1 | ||
| HIV-associated lymphoma (PBL, DLBCL, HL) | 5 | ||
| Hodgkin lymphoma, n (%) | 11 (20%) |
| . | All (N = 55) . | Phase 1b (n = 25) . | Phase 2 (N = 30) . |
|---|---|---|---|
| Median age, y (range) | 60 (19-84) | 58 (19-84) | 67 (23-81) |
| Male/female, n/n | 35/20 | 17/8 | 18/12 |
| ECOG performance status, n (%) | |||
| 0-1 | 48 (87%) | 23 (92%) | 25 (83%) |
| 2 | 7 (13%) | 2 (8%) | 5 (17%) |
| Stage | |||
| I-II | 9 (16%) | 6 (24%) | 3 (10%) |
| III-IV | 46 (84%) | 19 (76%) | 27 (90%) |
| Previous lines of antineoplastic therapy, n (%) | |||
| 1 | 13 (24%) | 5 (20%) | 8 (27%) |
| 2 | 19 (35%) | 9 (36%) | 10 (33%) |
| ≥3 | 23 (42%) | 11 (44%) | 12 (40%) |
| Median, n (range) | 2 (1-11) | 2 (1-11) | 2 (1-6) |
| Prior therapies | |||
| Brentuximab vedotin, n (%) | 13 (24%) | 7 (28%) | 6 (20%) |
| AutoSCT/alloSCT, n (%) | 13 (24%) | 7 (28%) | 6 (20%) |
| Checkpoint inhibitor, n (%) | 9 (16%) | 5 (20%) | 4 (13%) |
| HDACi, n (%) | 5 (9%) | 3 (12%) | 2 (7%) |
| EBV CTL | 5 (9%) | 2 (8%) | 3 (10%) |
| Refractory to most recent regimen, n (%) | 41 (75%) | 17 (68%) | 24 (80%) |
| EBV+lymphoma diagnosis | |||
| B-NHL, n (%) | 10 (18%) | ||
| DLBCL, n | 7 | ||
| Other B-cell, n | 3∗ | ||
| T/NK-NHL, n (%) | 21 (38%) | ||
| Extranodal NK/T-cell lymphoma | 9 | ||
| PTCL NOS | 5 | ||
| Angioimmunoblastic T-cell lymphoma | 6 | ||
| Cutaneous T-cell lymphoma | 1 | ||
| Immunodeficiency-associated LPD, n (%) | 13 (24%) | ||
| Posttransplant lymphoproliferative disorder | 4 | ||
| Systemic lupus erythematosus | 2 | ||
| Common variable immune deficiency | 1 | ||
| Primary immunodeficiency | 1 | ||
| HIV-associated lymphoma (PBL, DLBCL, HL) | 5 | ||
| Hodgkin lymphoma, n (%) | 11 (20%) |
alloSCT, allogeneic SCT; autoSCT, autologous SCT; CTL, cytotoxic T lymphocytes; ECOG, Eastern Cooperative Oncology Group; HL, Hodgkin lymphoma; LPD, lymphoproliferative disorder; NHL, non-Hodgkin lymphoma; NK/T, natural killer/T-cell; PBL, plasmablastic lymphoma.
CD30+ B-cell lymphoma, B-LPD, and PBL.